实施疫苗伤害无过错补偿规划国家的经济与免疫安全监测特征
本研究对世界卫生组织194个成员国开展调查并获151国反馈,描述了实施疫苗伤害补偿规划的25个成员国的经济与疫苗安全监测特征。25国中20国为高收入国家,20国达到全球疫苗行动计划安全指标,21国达到DTP3覆盖指标,17国于2017年评估了疫苗犹豫。所有实施补偿规划的国家均设有国家免疫技术咨询组。
要点
- 25个实施疫苗伤害补偿规划的国家中,20个为高收入国家。
- 20/25国达到每10万人口至少10份年度免疫后不良事件报告的安全指标。
- 所有实施补偿规划的国家均设有国家免疫技术咨询组。
核心结论
- 实施疫苗伤害无过错补偿规划的国家以高收入国家为主,但高收入国家之外对此类规划的兴趣正在增长。
- 应制定适用于不同免疫规划成熟度国家的全球补偿指导政策。
研究设计与样本
- 对世界卫生组织全部194个成员国开展调查,收到151个成员国的反馈。
- 分析描述了25个实施疫苗伤害补偿规划成员国的经济、疫苗接种和安全监测指标特征。
主要发现
- 25个实施补偿规划的国家中,20个(80%)为高收入国家。
- 20/25(80%)达到全球疫苗行动计划安全指标,即每10万人口至少报告10份年度免疫后不良事件报告。
- 21/25(84%)达到全球疫苗行动计划覆盖指标,即百白破疫苗第三剂(DTP3)接种率大于90%。
- 17/25(68%)在2017年评估了疫苗犹豫。
- 所有实施疫苗伤害补偿规划的国家均设有国家免疫技术咨询组。
关键数值与推荐
- 截至2010年,194个世界卫生组织成员国中已识别并描述19个国家的疫苗相关伤害补偿规划,均位于工业化世界,低收入和中等收入国家没有此类规划。
临床怎么用
- 可为各国自我评估和未来补偿政策制定提供参考信息。
- 全球补偿政策讨论应覆盖免疫规划成熟度不同的国家。
局限性
- 调查仅收到151个成员国的反馈,未覆盖全部194个成员国。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Improvements in vaccine safety surveillance and investigative capacity lead to identification of rare reactions attributable to vaccination. As a result, the issue of fair compensation for those who experience vaccine injuries is gaining growing attention. Although vaccine injury compensation programmes (VICP) have been developed in a few countries for more than 50 years, no global policy guidance to guide vaccine injury compensation in all countries wishing to adopt such compensation schemes is currently available. To update the landscape analysis of no-fault compensation programmes and characterize VICP implementing countries, we conducted a survey of all 194 Member States from the World Health Organization and received feedback from 151. This analysis describes the economic and vaccine safety surveillance characteristics of Member States implementing VICPs. This analysis describes the characteristics of 25 Member States implementing a compensation programmes. Characteristics examined include economic, vaccination and safety surveillance indicators. Twenty of the 25 Member States (80%) with compensation programmes are categorized as high-income countries, 20/25 (80%) met the Global Vaccine Action Plan (GVAP) safety indicator of reporting at least ten annual reports of adverse events following immunization per 100,000 population, 21/25 (84%) met the GVAP coverage indicator by achieving greater than 90% third dose of Diphtheria, Tetanus and Pertussis vaccine (DTP3) and 17/25 (68%) assessed vaccine hesitancy in 2017. All Member States with VICP have a national immunization technical advisory group. This study identified growing interest in the implementation of no-fault compensation programs beyond high-income countries. Global policies guiding compensation should be developed for countries regardless of the maturity of their immunization programmes. RESEARCH IN CONTEXT: As a result of improved vaccine safety surveillance, World Health Organization (WHO) Member States are facing situations where known untoward serious vaccine reactions are documented, including in low- and middle-income settings. This has led to increased interest for the development of national no-fault compensation policies for vaccine injuries. As of 2010, compensation schemes for vaccine related injuries had been identified and characterized in 19 out of 194 WHO member states. All these programmes were in the industrialized world with none in low- and middle-income countries. Previous reviews have described the characteristics of the existing programmes based on the six common elements identified by Evans in 1999 with less emphasis on characteristics from countries implementing these no-fault compensation programmes. This manuscript aimed to identify predictors of countries implementing no-fault compensation programmes for vaccine injuries and update the inventory of existing programmes as part of a more comprehensive global landscape evaluation of existing programmes. This information will be useful for country self-evaluation and future compensation policy formulation as discussion to develop policies guiding the implementation of vaccine injury compensation continues to gain growing attention.
引用
- Mungwira RG, Maure CG, Zuber PLF, et al. Economic and immunisation safety surveillance characteristics of countries implementing no-fault compensation programmes for vaccine injuries. Vaccine. 2019. PMID: 31213377. doi:10.1016/j.vaccine.2019.06.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。